about
The bank of biological samples representing individuals exposed to long-term ionizing radiation at various doses.Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity.Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis.Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expressionInvasive and drug resistant expression profile of different morphological structures of breast tumors.Phenotypic drift as a cause for intratumoral morphological heterogeneity of invasive ductal breast carcinoma not otherwise specified.Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.Intratumor heterogeneity: nature and biological significance.The phenomenon of multi-drug resistance in the treatment of malignant tumors.Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer.GLCE rs3865014 (Val597Ile) polymorphism is associated with breast cancer susceptibility and triple-negative breast cancer in Siberian population.Circulating tumor cells in breast cancer: functional heterogeneity, pathogenetic and clinical aspects.Comprehensive meta-analytical summary on human papillomavirus association with head and neck cancer.Natural and Chemotherapy-Induced Clonal Evolution of Tumors.Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy.[Biological effects of interferon, produced by recombinant bacteria of the probiotic preparation subalin]Changing the expression vector of multidrug resistance genes is related to neoadjuvant chemotherapy response.The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.HPV status and its genomic integration affect survival of patients with cervical cancerDifferent patterns of allelic imbalance in sporadic tumors and tumors associated with long-term exposure to gamma-radiation[Modulation of the antitumor effect of cyclophosphamide by the recombinant probiotic Subalin][Role of macrophages in the antitumor action of the recombinant probiotic Subalin][Adjuvant properties of subalin, a recombinant interferon-producing probiotic][Effect of impulse-intermittent ultrahigh frequency irradiation on synthesis of nucleic acids in tumor cells]Cell-surface-bound circulating DNA as a prognostic factor in lung cancerAssociation between TP53 gene ARG72PRO polymorphism and chromosome aberrations in human cancers[Assay of methylated gene RARbeta2 in circulating DNA of blood from patients with lung cancer as a potential prognostic marker]Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapyHuman papillomavirus and colorectal cancerGenome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectivesAmplification of Stem Genes: New Potential Metastatic Makers in Patients with an Early Form of Breast CancerHuman papillomavirus and lung cancer: an overview and a meta-analysis[The frequency and spectrum of cytogenetic anomalies in employees of Siberian Group of Chemical Enterprises][Viral co-infection with head and neck tumors]
P50
Q33457105-E51F79E4-DE43-4F74-A601-1C25831FA8D3Q33607816-9272553A-4C4D-4322-BA84-2E60FECC871FQ33991836-6BBADC32-1D46-4169-B058-559F5897B9F4Q35149179-35444BC6-269C-4E6D-85D2-66A8B9B0F722Q35559547-AE46EE6C-FAF7-486D-ABE0-FDF8047C5EAFQ36750271-1FC6580D-44BE-4C36-9E80-86AB160E0D15Q36946637-A40743B7-27AB-44A8-A23B-731E3AABA57AQ38181614-ABA8F982-7694-471A-8A78-80C753052FEBQ38255246-417BF00D-311B-4796-9109-44A58B4F7897Q38287959-8C37F52C-CDAC-4BC5-90F2-11C499C2D1F5Q38666526-780EA2CB-9593-4DBD-8788-4CEB2B6ABC79Q38865173-7C0BD36E-491D-49CB-BAF7-E2B5ED53E490Q38880821-F58BAEF3-8ADD-4DB1-9F21-5BCBCD463D26Q39216808-641580CE-B90B-403D-896B-06F0168EDE1DQ39438531-6EBBB18B-14CF-4C73-AB40-B0DF9C400091Q43569487-62D92332-4C75-43D4-9522-CF861581ACB9Q45962835-4F660A5B-9A96-4784-B624-1C8C5C4DDDA7Q53784002-912C8305-1FC3-46EC-8E1C-F4B3506A6306Q54967714-314B9BBD-B402-447A-B1DE-982AE441DA18Q59360702-02791782-5CD1-447D-A230-549D9D64BFB7Q60731439-932E0320-E151-47F2-BCCF-521FC58C4F1CQ73560555-4616CC72-9570-4C9B-A551-48D3F723D016Q73795311-C2C2EF29-C744-40CC-8038-39EF3761EBEFQ77735988-7A9D2362-06E7-40E9-A702-0CD569EC6375Q81319610-7E15E4C2-4936-44A8-8FE3-DFBA6831EBC6Q82218686-C3D96CBC-46A8-4D46-939B-576C3CC57FDCQ84330909-14394B97-6B62-4526-8856-50268BAA900BQ84867465-CD18D1A7-769A-449A-94E6-EB8517473C88Q88574751-0957C7EF-8BF2-4ABA-B5B0-6FA03639EAD9Q91309238-AF383597-A142-4DB3-81C1-C7B52FF32B44Q91393339-C87E9768-7C01-4683-A057-82F473B4EA83Q92139814-08760C7C-5179-4EE2-956C-8EFBA191570EQ93005559-2E8AA9A8-436C-4E2B-BCB9-3EA9D6BA86DBQ95603119-0DE76C22-2AB5-4037-9EEB-6C37E876C3B3Q96020844-57EDE8BD-DE37-431A-B085-BCD89509DBD2
P50
description
researcher
@en
name
Litviakov NV
@nl
Nikolai V. Litviakov
@en
Nikolai Wassiljewitsch Litwjakow
@de
Николай Васильевич Литвяков
@ru
type
label
Litviakov NV
@nl
Nikolai V. Litviakov
@en
Nikolai Wassiljewitsch Litwjakow
@de
Николай Васильевич Литвяков
@ru
altLabel
Litviakov NV
@en
Nikolai Litviakov
@en
Nikolai Litwjakow
@de
Nikolay Litvyakov
@en
Nikolay Vasilyevich Litvyakov
@en
prefLabel
Litviakov NV
@nl
Nikolai V. Litviakov
@en
Nikolai Wassiljewitsch Litwjakow
@de
Николай Васильевич Литвяков
@ru
P106
P21
P31
P496
0000-0002-0714-8927